Literature DB >> 31647206

Dicer Sequencing, Whole Genome Methylation Profiling, mRNA and smallRNA Sequencing Analysis in Basal Cell Carcinoma.

Michael Sand1,2, Annabelle Bromba1, Daniel Sand3, Thilo Gambichler1, Schapoor Hessam1, Jürgen C Becker4,5,6, Eggert Stockfleth1, Thomas Meyer1, Falk G Bechara1.   

Abstract

BACKGROUND/AIMS: Perturbations in the expression of microRNAs (miRNAs) and their maturing machinery components such as Dicer have been previously described for basal cell carcinoma (BCC). However, the mutational status of Dicer in BCC is unclear. Further, the sclerodermiform subtype of BCC (sBCC) has not been previously investigated regarding its methylation profile or its smallRNA expression profile via RNA sequencing. We conducted this study to investigate the mutational status of Dicer in BCC.
METHODS: Dicer sequencing was performed on the Illumina MiSeq System in a total of 16 BCC samples (8 nodular BCCs, 8 sBCCs) and mapped against the human reference genome (i.e., hg19). Dicer sequencing was performed in all 16 BCC samples. We performed whole genome methylation profiling with Infinium MethylationEPIC BeadChips as well as mRNA and smallRNA sequencing in 5 sBCCs with the Illumina NextSeq500 next-generation sequencing system.
RESULTS: Compared to the wildtype Dicer sequence, we found 5 to 7 variants per sBCC sample including insertion, deletion, and multiple nucleotide variants. Global methylation profiles were highly similar between groups. mRNA sequencing revealed S100A9, KRT14, KRT10, S100A8, S100A7, COX1, KRT1, COX3, and smallRNA sequencing analysis miR-21, miR-99a, miR26-a-2, let-7f, let-7g, let-7i, miR-100, and miR-205 were the most strongly expressed in sBCCs.
CONCLUSION: We identified a variety of Dicer mutations that could play a role in aberrant miRNA expression in BCC. The noted RNA sequences should be further evaluated in functional studies to explore their potential pathogenetic role in sBCC. © Copyright by the Author(s). Published by Cell Physiol Biochem Press.

Entities:  

Keywords:  Basal cell carcinoma; Epithelial skin cancer; smallRNA; microRNA; Dicer; Methylation; Microarray

Mesh:

Substances:

Year:  2019        PMID: 31647206     DOI: 10.33594/000000171

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  5 in total

1.  High mutation burden in the checkpoint and micro-RNA processing genes in myelodysplastic syndrome.

Authors:  Ivan Sergeevich Moiseev; Nikolay Yurevich Tcvetkov; Ildar Munerovich Barkhatov; Maria Vladimirovna Barabanshikova; Dmitrii Sergeevich Bug; Natalya Vitalievna Petuhova; Artem Valerievich Tishkov; Evgenyi Alexandrovich Bakin; Ekaterina Andreevna Izmailova; Alena Igorevna Shakirova; Alexandr Dmitrievich Kulagin; Elena Vladislavovna Morozova
Journal:  PLoS One       Date:  2021-03-17       Impact factor: 3.240

2.  Profile of Basal Cell Carcinoma Mutations and Copy Number Alterations - Focus on Gene-Associated Noncoding Variants.

Authors:  Paulina Maria Nawrocka; Paulina Galka-Marciniak; Martyna Olga Urbanek-Trzeciak; Ilamathi M-Thirusenthilarasan; Natalia Szostak; Anna Philips; Laura Susok; Michael Sand; Piotr Kozlowski
Journal:  Front Oncol       Date:  2021-11-25       Impact factor: 6.244

3.  The circular RNA circFARSA sponges microRNA-330-5p in tumor cells with bladder cancer phenotype.

Authors:  Chen Fang; Xin Huang; Jun Dai; Wei He; Le Xu; Fukang Sun
Journal:  BMC Cancer       Date:  2022-04-08       Impact factor: 4.638

4.  Differentiation-related epigenomic changes define clinically distinct keratinocyte cancer subclasses.

Authors:  Manuel Rodríguez-Paredes; Frank Lyko; Llorenç Solé-Boldo; Günter Raddatz; Julian Gutekunst; Oliver Gilliam; Felix Bormann; Michelle S Liberio; Daniel Hasche; Wiebke Antonopoulos; Jan-Philipp Mallm; Anke S Lonsdorf
Journal:  Mol Syst Biol       Date:  2022-09       Impact factor: 13.068

Review 5.  Basal Cell Carcinoma: A Comprehensive Review.

Authors:  Emi Dika; Federica Scarfì; Manuela Ferracin; Elisabetta Broseghini; Emanuela Marcelli; Barbara Bortolani; Elena Campione; Mattia Riefolo; Costantino Ricci; Martina Lambertini
Journal:  Int J Mol Sci       Date:  2020-08-04       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.